Atanas G. Atanasov´sPhD

senior researcher
Department of Pharmacognosy
University of Vienna

Dr. Atanas G. Atanasov´s research focuses on molecular mechanisms 

of pharmacological action in the context of inflammation and 

cardiometabolic disease, and natural product-based drug discovery. 

Since 2008, he is a senior researcher at Department of 

Pharmacognosy, University of Vienna, where he was actively 

involved in the execution of the Austrian national network “Drugs 

From Nature Targeting Inflammation” (DNTI), a collaborative 

research project which has been financed with >3 000 000 Euro from 

the Austrian Science Fund. In recognition of his overall 

achievements, Dr. Atanasov has been awarded in 2012 with “Focus of 

Excellence” fellowship by the Faculty of Life Sciences, University 

of Vienna. In addition to traditional ways for scientific 

dissemination (peer reviewed research publications, conference 

contributions etc.), Dr. Atanasov has been very successful in 

respect of direct science communication in the Social Media 

(KloutScore = 78).

Research Interests

Molecular mechanisms of pharmacological action
Cell signalling and regulatory pathways relevant for inflammation 

and cardiometabolic disease
Discovery and characterisation of novel bioactivities of natural 

Use of small molecules as tools for biological systems 

manipulation and basic research (chemical biology).  

Scientific Activities

Mehdi RazaviPhD

Helmerich Advanced Technology Research Center
Oklahoma State University

Dr. Mehdi Razavi joined as a Research Scholar to Helmerich Advanced Technology Research Center at Oklahoma State University (OSU) from 2013 to 2014. He received his PhD in Biomaterials from Isfahan University of Technology/Isfahan University of Medical Sciences in 2014, MS in Materials Engineering from Isfahan University of Technology in 2010 and BS in Materials Engineering from Isfahan University of Technology in 2008. As one of his research honors, the Graduate Committee at Isfahan University of Technology distinguished Dr. Razavi as the author of Best PhD Thesis in 2011-2014. Dr. Razavi is an accomplished researcher in the field of Biomaterials science, focusing on Tissue Engineering and Regenerative Medicine, In vitro studies, In vivo animal models, 3D scaffold design, Cell Biology, Surface and Biointerface science, Bio-corrosion engineering, Biomechanical studies, and Biodegradable metals and using this knowledge to develop advanced materials for wound therapies. Dr. Razavi also serves as the author, reviewer and member of the editorial boards of numerous recognized international journals.


Research Interests

Tissue Engineering and Regenerative Medicine
In vitro studies
In vivo animal models
3D scaffold design
Cell Biology
Surface and Biointerface science
Corrosion engineering
Biomechanical studies
Biodegradable metals

Scientific Activities

Hongwu DuPhD

Deputy Chair

University of Science & Technology
Address:Beijing, China

Hongwu Du, Ph.D., holds faculty appointment of systems biology at the University of Science and Technology Beijing since 2007, and serves the Deputy Chair with the Key Laboratory of Bioengineering & Biosensing of Beijing which he founded in China in 2012. Prior to taking up his tenure position at USTB, he was a Senior Scientist at the National Engineering Research Center for Beijing Biochip Technology (2000-2006), and served in a variety of senior positions in high-tech and listed company.
He is the author of numerous articles on systems biology both for technology development and clinical application, also principal investigator for some important projects including Pesticide residues in wheat, Mycotoxins antibody preparation and testing systems, Screening drug target for autoimmune diseases, Identification of exogenous growth hormone, New hMGF interacting proteins mediated screening and molecular mechanisms of muscle regeneration, Detection of doping, Human Growth Hormone subtype-specific monoclonal antibody and trace Detection, rhEPO and rhGH detection method etc.

Research Interests

Pesticide residues in wheat
Mycotoxins antibody preparation and testing systems
Screening drug target for autoimmune diseases
Identification of exogenous growth hormone
New hMGF interacting proteins mediated screening and molecular mechanisms of muscle regeneration 
Detection of doping
Human Growth Hormone subtype-specific monoclonal antibody and trace Detection RhEPO and rhGH detection method etc.


Scientific Activities

Jie MaPhD


State Key Laboratory of Molecular Oncology

JieMa is a ProfessorofImunology,State Key Laboratory of 

Molecular Oncology,CAMS,2008 

now.AssociateProfessorofImunology,State Key Laboratory of 

Molecular Oncology,CAMS,2000-2008.Assistant Professorof 

Biochemistry, University of Alberta,1998-2000.Researcher, 

AltaRexbiological product company,1996-1998.Postdoctoral 

researcher of Pharmacology , University of Alberta,1994-

1996.She also work as a Editorial of journals Deputy editor of 

Cancer Progression(chinease). Editor of Frontiers in Cancer 

Molecular Targets and Therapeutics. Her research interests 

focused on Search new biomarkers of cancer diagnosis and 

targets against metastasis.Identify several microRNAs 

associated with metastasis of colorectal cancer and drug-

resistance of pancreatic cancer,Study their functions and 

mechanisms to find potential drug targets.Select and validate 

several microRNAs and protein biomarkers for diagnosis and 

prognosis prediction of pancreatic cancer.Discover new drug and 

develop new delivery system targeting cancer molecule using 

nanotechnology.Collaborated with chemists of Beijing 

University, we are evaluating new nanomaterials as anti-cancer 

drugs. Because of the unique physical characters, nanomaterial 

has special ability disturbing tumor growth. However, the 

mechanism of this anti-cancer function has not been declared. 

Our results revealed that some of these nanomaterials could 

induce a cascade of immune response in vivo, which caused a 

mild anti-cancer effect. Using nanospheres, we developed a 

colon targeting drug delivery system, which could inhibit the 

growth of colon cancer. This nanosphere is pH sensitive and 

able to dissolve oil soluble chemodrugs. Also, the application 

of the nanosphere could change drug administration rout from 

i.v. to oral, which has a better compliance with patient.
Research on cancer immunology and Biotherapy for cancer.
Developand conduct adoptive cell therapy to cancer patients in 

our hospital;
Research on functions and mechanisms of immune cells, such as 

T-cell, B-cell, macrophage, in the development of cancer.

Research Interests

Targets against metastasis
Identify several microRNAs associated with metastasis of 

colorectal cancer and drug-resistance of pancreatic cancer
Study their functions and mechanisms to find potential drug 

Select and validate several microRNAs and protein biomarkers 

for diagnosis and prognosis prediction of pancreatic cancer
Discover new drug and develop new delivery system targeting 

cancer molecule using nanotechnology
Collaborated with chemists of Beijing University
we are evaluating new nanomaterials as anti-cancer drugsBecause 

of the unique physical characters

Scientific Activities